Wechselwirkungen · Selincro
Selincro 18 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-127547 · Präparat HOS-096425
Based on in vitro studies, no clinically relevant interactions between nalmefene, or its metabolites, and concomitantly administered medicinal products metabolised by the most common CYP450 and UGT enzymes or membrane transporters are anticipated. Co-administration with medicinal products that are potent inhibitors of the UGT2B7 enzyme (for example, diclofenac, fluconazole, medroxyprogesterone acetate, meclofenamic acid) may significantly increase the exposure to nalmefene. This is unlikely to present a problem with occasional use, but if long-term concurrent treatment with a potent UGT2B7 inhibitor is initiated, a potential for an increase in nalmefene exposure cannot be excluded (see section 4.4). Conversely, concomitant administration with a UGT inducer (for example, dexamethasone, phenobarbital, rifampicin, omeprazole) may potentially lead to subtherapeutic nalmefene plasma concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): meclofenamic acid (HOS-127550) diclofenac (HOS-085903) acetate (HOS-088133) phenobarbital (HOS-085617) nalmefene (HOS-115837) dexamethasone (HOS-084535) lead (HOS-085592) medroxyprogesterone (HOS-088132) fluconazole (HOS-087945) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-07T14:41:00Z · SHA-256 33e306a05073974202b9dcd16eeb2a7e14ad94d43e4edbbf04adc0b88df7e8a1 · Passage f4955a4d19632a870b602e2f1608f5fccd1b9a74fd877ed6f9cb03c3731a9040 · Zeichen 63–969 im Abschnitt